Related Experiment Video
Updated: Feb 11, 2026

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
Published on: January 20, 2023
Discovery of new benzensulfonamide derivatives as tripedal STAT3 inhibitors
Jianpeng Guo1, Wenying Yu1, Guiping Cai1
1Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing, 210009, People's Republic of China.
Abstract:
Persistent activated STAT3 has a striking correlation with cancer development and inhibition of STAT3 signaling pathway is a novel therapeutic way for human cancers. Among STAT family, STAT1 and STAT3 play opposite roles in tumorigenesis. However, the discovery of selective STAT3 inhibitors is still challenging to date. In this study, a series of small-molecular (MW < 500) benzensulfanilamide derivatives were designed to selectively suppress STAT3 activation for anti-cancer treatment. The most potent compound 11 inhibited both overexpressed and IL-6 induced STAT3 phosphorylation, whereas 11 displayed little effect on the phosphorylation of other STAT isoforms STAT1, STAT5, demonstrating 11 was a selective STAT3 inhibitor. Meanwhile, 11 dismissed STAT3 DNA binding activity and colony formation. In addition, 11 elevated the ROS level and induced apoptosis of cancer cells. Furthermore, 11 effectively suppressed tumor growth in an in vivo mouse-xenograft model.
Insights
Researchers developed a novel benzensulfanilamide derivative that selectively inhibits Signal Transducer and Activator of Transcription 3 (STAT3) activation. This compound effectively suppressed cancer cell growth and tumor development in preclinical models.
Area of Science:
- Oncology
- Molecular Biology
- Medicinal Chemistry
Background:
- Persistent activation of Signal Transducer and Activator of Transcription 3 (STAT3) is linked to cancer development.
- STAT3 signaling pathway inhibition is a promising anti-cancer therapeutic strategy.
- Selective STAT3 inhibitors are challenging to discover, as STAT1 and STAT3 have opposing roles in tumorigenesis.
Purpose of the Study:
- To design and synthesize small-molecule benzensulfanilamide derivatives targeting STAT3 activation.
- To identify selective STAT3 inhibitors for potential anti-cancer therapy.
Main Methods:
- Design and synthesis of small-molecule benzensulfanilamide derivatives (MW < 500).
- Evaluation of compound inhibitory effects on STAT3 phosphorylation (overexpressed and IL-6 induced).
- Assessment of compound selectivity against other STAT isoforms (STAT1, STAT5).
- In vitro assays for STAT3 DNA binding activity, colony formation, ROS levels, and apoptosis.
- In vivo efficacy study using a mouse-xenograft model.
Main Results:
- Compound 11 selectively inhibited STAT3 phosphorylation without affecting STAT1 or STAT5.
- Compound 11 reduced STAT3 DNA binding activity and colony formation in cancer cells.
- Compound 11 induced apoptosis and elevated reactive oxygen species (ROS) levels.
- Compound 11 demonstrated significant tumor growth suppression in vivo.
Conclusions:
- Benzensulfanilamide derivative 11 is a potent and selective STAT3 inhibitor.
- Compound 11 exhibits anti-cancer properties through multiple mechanisms, including apoptosis induction.
- This compound shows therapeutic potential for treating cancers driven by STAT3 activation.
More Related Videos
Related Concept Videos
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Drug Discovery: Overview
Dipeptidyl Peptidase 4 Inhibitors
Measurement: Derived Units
Antihypertensive Drugs: Direct Renin Inhibitors
Higher Derivatives

